Novartis: New NIBR director named. Entresto closer to be available EU
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
Pharmaceuticals, Biotechnology and Life Sciences
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
Novartis has announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and…
Treatment with clomiphene, a standard therapy for couples with unexplained infertility, results in more live births than treatment with a…
Amgen and Allergan plc. announced on Wednesday that a Phase 3 study of biosimilar candidate ABP 215 met its primary…
ViiV Healthcare announced on Wednesday 24-week data from the Phase IIIb/IV Striiving study, an open-label study evaluating the efficacy, safety…
FDA is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and…
US presidential candidate from Democratic party, Hilary Clinton, has announced to make a plan about pricing medicine. After the news spread…
Biofrontera, the biopharmaceutical company focusing on sun-induced skin cancer, has announced that preliminary long-term results of the Phase III trial for…
Bayer announced on September 22 that Bayer CropScience and the civil organization Round Table on Responsible (RTRS) are uniting to…
You must be logged in to post a comment.